Literature DB >> 8807740

Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat.

R N Clark1, C R Ashby, S L Dewey, P V Ramachandran, R E Strecker.   

Abstract

Recent studies indicate that an increase in serotonergic (5-HT) activity in the nucleus accumbens (NAc) produces an increase in dopamine (DA) release, providing a possible mechanism for the involvement of DA in the therapeutic action of selective serotonin reuptake inhibitor (SSRI) antidepressants. However, acutely administered fluoxetine (2.5, 5.0, or 10.0 mg/kg, i.p.) failed to elevate extracellular levels of DA, or its metabolites in the NAc or caudate-putamen (CP). In fact, the highest dose produced a small (20%) decrease in DA levels in the NAc. Extracellular levels of the 5-HT metabolite 5HIAA were consistently decreased at all doses of fluoxetine in both structures. Since SSRIs generally require several weeks of treatment to be effective clinically, a second experiment examined the effect of chronic administration of fluoxetine. Chronic (21 day) daily treatment with 5 mg/kg had no effect on NAc basal levels of DA, DA metabolites, or 5HIAA, relative to a saline-treated control group. Finally, pretreatment with fluoxetine appeared to slightly enhance the elevation of NAc DA induced by an injection of cocaine (10 mg/kg, i.p.), an effect that was not quite significant (P < .06). In conclusion, the 5-HT-induced facilitation of NAc DA neurotransmission described in the literature may not be relevant to the therapeutic action of fluoxetine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807740     DOI: 10.1002/(SICI)1098-2396(199607)23:3<125::AID-SYN1>3.0.CO;2-A

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  9 in total

1.  Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.

Authors:  E K Sawyer; L L Howell
Journal:  Pharmacology       Date:  2011-07-14       Impact factor: 2.547

2.  Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants.

Authors:  Robert C Drugan; Heather Macomber; Timothy A Warner
Journal:  Psychopharmacology (Berl)       Date:  2010-07-10       Impact factor: 4.530

3.  Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum.

Authors:  Charles H K West; Jay M Weiss
Journal:  Int J Neuropsychopharmacol       Date:  2010-05-19       Impact factor: 5.176

Review 4.  Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.

Authors:  Leonard L Howell; Kathryn A Cunningham
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

5.  Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell.

Authors:  David T Chau; Pedro V Rada; Kay Kim; Rebecca A Kosloff; Bartley G Hoebel
Journal:  Neuropsychopharmacology       Date:  2011-04-27       Impact factor: 7.853

6.  Sex and social status modify the effects of fluoxetine on socioemotional behaviors in Syrian hamsters and rhesus macaques.

Authors:  Dené A Voisin; Alison Wakeford; Jonathon Nye; Jiyoung Mun; Sara R Jones; Jason Locke; Kim L Huhman; Mark E Wilson; H Elliott Albers; Vasiliki Michopoulos
Journal:  Pharmacol Biochem Behav       Date:  2022-02-24       Impact factor: 3.533

7.  Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices.

Authors:  Carrie E John; Sara R Jones
Journal:  Neuropharmacology       Date:  2007-03-16       Impact factor: 5.250

8.  Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine.

Authors:  Damiaan Denys; André A Klompmakers; Herman G M Westenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-05-11       Impact factor: 4.530

9.  The Combination of Galanin (1-15) and Escitalopram in Rats Suggests a New Strategy for Alcohol Use Disorder Comorbidity with Depression.

Authors:  Noelia Cantero-García; Antonio Flores-Burgess; David Ladrón de Guevara-Miranda; Antonia Serrano; Laura García-Durán; Araceli Puigcerver; Kjell Fuxe; José Ángel Narváez; Luis Javier Santín; Zaida Díaz-Cabiale; Carmelo Millón
Journal:  Biomedicines       Date:  2022-02-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.